HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhang, N. Articles by Deuel, T. F. Search for Related Content PubMed PubMed Citation Articles by Zhang, N. Articles by Deuel, T. F. Social Bookmarking                      What's this?

Volume 272, Number 27, Issue of July 4, 1997 pp. 16733-16736
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

COMMUNICATION:
Human Breast Cancer Growth Inhibited in Vivo by a Dominant Negative Pleiotrophin Mutant

(Received for publication, April 11, 1997, and in revised form, May 13, 1997)

From the Division of Growth Regulation, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215

Pleiotrophin (PTN) is a recently described 18- kDa heparin binding growth/differentiation factor. It also is a proto-oncogene; cells transformed by the Ptn gene form highly angiogenic tumors when implanted into the nude mouse. PTN may be an important regulator of transformation in other tumors, because constitutively high levels of expression of the pleiotrophin (Ptn) gene are found in human breast cancer and other malignant cell lines, and its levels of expression are high in many human tumor specimens. To determine whether PTN is an important regulator of the malignant phenotype of human breast cancer cells, we constructed a mutant cDNA to encode a truncated PTN designed to heterodimerize with the product of the endogenous Ptn gene during processing. The mutant gene product blocked transformation of NIH 3T3 cells by the wild type (wt) Ptn gene product. The mutant Ptn cDNA was then introduced into human breast cancer MDA-MB-231 cells, and clonal lines that stably express the mutant Ptn cDNA were selected. The truncated PTN was shown to form heterodimers with the endogenous Ptn gene product in these cells. Furthermore, the MDA-MB-231 cells that express the mutant Ptn gene were no longer transformed; they failed to form plaques or colonies in soft agar and were unable to form tumors in the athymic nude mouse. The results establish an important role of PTN in the dysregulated growth of human breast cancer cells and suggest that constitutive expression of PTN may be essential to the malignant phenotype of human breast cancers in vivo.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. Landgraf, P. Wahle, H.-C. Pape, E. D. Gundelfinger, and M. R. Kreutz The Survival-promoting Peptide Y-P30 Enhances Binding of Pleiotrophin to Syndecan-2 and -3 and Supports Its Neuritogenic Activity J. Biol. Chem., September 5, 2008; 283(36): 25036 - 25045. [Abstract] [Full Text] [PDF]

				H. Chen, M. S. Gordon, R. A. Campbell, M. Li, C. S. Wang, H. J. Lee, E. Sanchez, S. J. Manyak, D. Gui, D. Shalitin, et al. Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth Blood, July 1, 2007; 110(1): 287 - 295. [Abstract] [Full Text] [PDF]

				Y. Chang, M. Zuka, P. Perez-Pinera, A. Astudillo, J. Mortimer, J. R. Berenson, and T. F. Deuel Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment PNAS, June 26, 2007; 104(26): 10888 - 10893. [Abstract] [Full Text] [PDF]

				H. Pariser, G. Herradon, L. Ezquerra, P. Perez-Pinera, and T. F. Deuel Pleiotrophin regulates serine phosphorylation and the cellular distribution of {beta}-adducin through activation of protein kinase C PNAS, August 30, 2005; 102(35): 12407 - 12412. [Abstract] [Full Text] [PDF]

				A. Polykratis, P. Katsoris, J. Courty, and E. Papadimitriou Characterization of Heparin Affin Regulatory Peptide Signaling in Human Endothelial Cells J. Biol. Chem., June 10, 2005; 280(23): 22454 - 22461. [Abstract] [Full Text] [PDF]

				E. T. Bowden, G. E. Stoica, and A. Wellstein Anti-apoptotic Signaling of Pleiotrophin through Its Receptor, Anaplastic Lymphoma Kinase J. Biol. Chem., September 20, 2002; 277(39): 35862 - 35868. [Abstract] [Full Text] [PDF]

				C. M. D'Cruz, S. E. Moody, S. R. Master, J. L. Hartman, E. A. Keiper, M. B. Imielinski, J. D. Cox, J. Y. Wang, S. I. Ha, B. A. Keister, et al. Persistent Parity-Induced Changes in Growth Factors, TGF-{beta}3, and Differentiation in the Rodent Mammary Gland Mol. Endocrinol., September 1, 2002; 16(9): 2034 - 2051. [Abstract] [Full Text] [PDF]

				I. Bernard-Pierrot, J. Delbe, V. Rouet, M. Vigny, M.-E. Kerros, D. Caruelle, D. Raulais, D. Barritault, J. Courty, and P. E. Milhiet Dominant Negative Effectors of Heparin Affin Regulatory Peptide (HARP) Angiogenic and Transforming Activities J. Biol. Chem., August 23, 2002; 277(35): 32071 - 32077. [Abstract] [Full Text] [PDF]

				G. E. Stoica, A. Kuo, A. Aigner, I. Sunitha, B. Souttou, C. Malerczyk, D. J. Caughey, D. Wen, A. Karavanov, A. T. Riegel, et al. Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin J. Biol. Chem., May 11, 2001; 276(20): 16772 - 16779. [Abstract] [Full Text] [PDF]

				K. Meng, A. Rodriguez-Pena, T. Dimitrov, W. Chen, M. Yamin, M. Noda, and T. F. Deuel Pleiotrophin signals increased tyrosine phosphorylation of beta -catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta /zeta PNAS, March 14, 2000; 97(6): 2603 - 2608. [Abstract] [Full Text] [PDF]